Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.
Omar R VayaniMaria E KaufmanKelley MooreMohansrinivas ChennakesavaluRachel TerHaarGepoliano ChavesAlexandre ChlenskiChuan HeSusan L CohnMark A ApplebaumPublished in: Pediatric blood & cancer (2023)
While it is feasible to identify ADRN and MES signatures using 5-hmC profiles of cfDNA from neuroblastoma patients and correlate these signatures to metastatic burden, additional data are needed to determine the optimal strategies for clinical implementation. Prospective evaluation in larger cohorts is ongoing.
Keyphrases
- end stage renal disease
- small cell lung cancer
- squamous cell carcinoma
- genome wide
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- primary care
- stem cells
- young adults
- bone marrow
- prognostic factors
- peritoneal dialysis
- risk factors
- patient reported outcomes
- electronic health record
- big data
- dna methylation
- artificial intelligence